Canopy Growth (CGC) Income from Non-Controlling Interests (2019 - 2025)
Canopy Growth (CGC) posted Income from Non-Controlling Interests of $95.5 million for Q4 2025, up 965.96% sequentially from -$11.0 million in Q3 2023.
Canopy Growth (CGC) Income from Non-Controlling Interests (2019 - 2025) Analysis & Trends
Canopy Growth has reported Income from Non-Controlling Interests for 6 years, with the latest figure at $95.5 million in Q4 2025.
- Quarterly Income from Non-Controlling Interests changed N/A year-over-year to $95.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $84.5 million (changed N/A YoY) and the FY2025 annual result came in at -$1.3 million, changed N/A from the prior year.
- Income from Non-Controlling Interests climbed to $95.5 million in Q4 2025 per CGC's latest filing, from -$11.0 million in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $95.5 million in Q4 2025 and troughed at -$11.0 million in Q3 2023.
- A 4-year average of $4.7 million and a median of -$3.7 million in 2022 frame the typical range for Income from Non-Controlling Interests.
- The sharpest annual moves came in 2022 and 2023: Income from Non-Controlling Interests soared 198.06% in 2022, then slumped 1015.95% in 2023.
- Over 4 years, Income from Non-Controlling Interests stood at -$5.2 million in 2021, then surged by 38.26% to -$3.2 million in 2022, then slumped by 242.67% to -$11.0 million in 2023, then soared by 965.96% to $95.5 million in 2025.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered $95.5 million, -$11.0 million, and -$2.8 million for Q4 2025, Q3 2023, and Q2 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 376,434.15 |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Canopy Growth | 434.93 Mn | 187.92 Mn | 16.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 95.51 Mn |
| Sep 30, 2023 | -11.03 Mn |
| Jun 30, 2023 | -2.78 Mn |
| Mar 31, 2023 | -5.57 Mn |
| Dec 31, 2022 | -3.22 Mn |
| Sep 30, 2022 | -988,335.91 |
| Jun 30, 2022 | -4.16 Mn |
| Mar 31, 2022 | 6.89 Mn |
| Dec 31, 2021 | -5.21 Mn |
| Sep 30, 2021 | -4.19 Mn |
| Jun 30, 2021 | -2.00 Mn |
| Mar 31, 2021 | -7.03 Mn |
| Dec 31, 2020 | 57.63 Mn |
| Sep 30, 2020 | -48.40 Mn |
| Jun 30, 2020 | -7.69 Mn |
| Mar 31, 2020 | -17.44 Mn |
| Dec 31, 2019 | -13.85 Mn |
| Sep 30, 2019 | -12.33 Mn |
| Jun 30, 2019 | -6.12 Mn |